Incyte Corporation
INCYIncyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia.
Drugs in Pipeline
67
Phase 3 Programs
28
Upcoming Catalysts
13
Next Catalyst
This month
Market Overview
Stock performance and key metrics
16 upcoming, 4 past
INCA034176 Phase 2 Results Expected
Primary completion for INCA034176 trial (NCT06843408) in Chronic Graft-versus-host-disease
Phase 2 trial failure led to discontinuation of development for hidradenitis suppurativa indication
Source15 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How INCY's past catalysts played out
Ruxolitinib
MPN (Myeloproliferative Neoplasms)
Lenalidomide
Large B-Cell Lymphoma
Pemetrexed
Metastatic Squamous Non-Small Cell Lung Cancer
Epacadostat
Lung Cancer
Tacrolimus (Tac)
Graft-versus-host Disease (GVHD)
carboplatin
Squamous Cell Carcinoma of the Anal Canal
Cyclophosphamide
Diffuse Large B-cell Lymphoma
Extracorporeal photopheresis (ECP)
Graft-versus-host Disease (GVHD)
ibrutinib
Lymphoma
Ruxolitinib Cream
Nonsegmental Vitiligo With Genital Involvement
Povorcitinib
NonSegmental Vitiligo
Itacitinib
MPN (Myeloproliferative Neoplasms)
Prednisone
Graft-versus-host Disease (GVHD)
Corticosteroids
Chronic Graft-versus-host-disease
Hydroxyurea (HU)
Polycythemia Vera
ruxolitinib tablets
Polycythemia Vera
Pembrolizumab
Head and Neck Cancer
pembrolizumab + epacadostat
Melanoma
Retifanlimab
Metastatic Merkel Cell Carcinoma
Tafasitamab
Diffuse Large B Cell Lymphoma
Bendamustine (BEN)
Diffuse Large B-cell Lymphoma
INCB123667
Ovarian Cancer
Investigator's choice of chemotherapy
Ovarian Cancer
INCA33890
CRC (Colorectal Cancer)
INCB161734
Solid Tumors
Sunitinib
Renal Cell Carcinoma (RCC)
rituximab
Follicular Lymphoma
INCA034176
Chronic Graft-versus-host-disease
Capecitabine
Pancreatic Cancer
parsaclisib + itacitinib
B-Cell Malignancies
Oxaliplatin
Solid Tumor
MEDI4736
Solid Tumors
Ruxolitinib 1.5% cream
Vitiligo
Regorafenib
Pancreatic Cancer
Osimertinib
Lung Cancer
MK-3475
Microsatellite-instability (MSI) High Colorectal Cancer (CRC)
INCA000585
Immune Thrombocytopenia
INCAGN01876
Advanced Malignancies
INCAGN01949
Advanced Malignancies
R-CHOP
Non Hodgkins Lymphoma
INCB001158
Biliary Tract Cancer (BTC)
INCB177054
Solid Tumors
ICS-LABA
Moderate to Severe Asthma
Pemigatinib
Non-Small Cell Lung Cancer (NSCLC)
Ruxolitinib 25 mg
Multiple Myeloma
Nivolumab
B-cell Malignancies
Asparaginase Erwinia Chrysanthemi
Leukemia
INCB013739
Type 2 Diabetes
INCB000928
Anemia
Ruxolitinib phosphate cream
Psoriasis
INCB054707
Hidradenitis Suppurativa
Parsaclisib
B-Cell Malignancies
Ponatinib
Philadelphia Positive
Ruxolitinib 0.15% Cream QD
Atopic Dermatitis
INCB009471
HIV Infections
INCB099280
Advanced Solid Tumor
INCAGN02385
Endometrial Cancer
Axatilimab
Chronic Graft-versus-host-disease
INCAGN02390
Melanoma
Best available Treatment (BAT)
Chronic Graft-versus-host-disease
Gemcitabine
Solid Tumors
INCB018424
Rheumatoid Arthritis
INCB028050
Rheumatoid Arthritis
Prednisone or methylprednisolone
Graft-versus-host Disease (GVHD)
Ruxolitinib Phosphate
Psoriasis
Immune effector cell therapy
Cytokine Release Syndrome
Platinum-based chemotherapy
Lung Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Ruxolitinib | Phase 3 | MPN (Myeloproliferative Neoplasms) | - | Patent 2041 |
Lenalidomide | Phase 3 | Large B-Cell Lymphoma | - | - |
Pemetrexed | Phase 3 | Metastatic Squamous Non-Small Cell Lung Cancer | - | Patent 2036 |
Epacadostat | Phase 3 | Lung Cancer | - | - |
Tacrolimus (Tac) | Phase 3 | Graft-versus-host Disease (GVHD) | - | - |
carboplatin | Phase 3 | Squamous Cell Carcinoma of the Anal Canal | - | - |
Cyclophosphamide | Phase 3 | Diffuse Large B-cell Lymphoma | - | - |
Extracorporeal photopheresis (ECP) | Phase 3 | Graft-versus-host Disease (GVHD) | - | - |
ibrutinib | Phase 3 | Lymphoma | - | - |
Ruxolitinib Cream | Phase 3 | Nonsegmental Vitiligo With Genital Involvement | - | - |
Povorcitinib | Phase 3 | NonSegmental Vitiligo | - | - |
Itacitinib | Phase 3 | MPN (Myeloproliferative Neoplasms) | - | - |
Prednisone | Phase 3 | Graft-versus-host Disease (GVHD) | - | - |
Corticosteroids | Phase 3 | Chronic Graft-versus-host-disease | - | - |
Hydroxyurea (HU) | Phase 3 | Polycythemia Vera | - | - |
ruxolitinib tablets | Phase 3 | Polycythemia Vera | - | - |
Pembrolizumab | Phase 3 | Head and Neck Cancer | - | - |
pembrolizumab + epacadostat | Phase 3 | Melanoma | - | - |
Retifanlimab | Phase 3 | Metastatic Merkel Cell Carcinoma | - | - |
Tafasitamab | Phase 3 | Diffuse Large B Cell Lymphoma | - | - |
Bendamustine (BEN) | Phase 3 | Diffuse Large B-cell Lymphoma | - | - |
INCB123667 | Phase 3 | Ovarian Cancer | - | - |
Investigator's choice of chemotherapy | Phase 3 | Ovarian Cancer | - | - |
INCA33890 | Phase 3 | CRC (Colorectal Cancer) | - | - |
INCB161734 | Phase 3 | Solid Tumors | - | - |
Sunitinib | Phase 3 | Renal Cell Carcinoma (RCC) | - | - |
rituximab | Phase 3 | Follicular Lymphoma | - | - |
INCA034176 | Phase 3 | Chronic Graft-versus-host-disease | - | - |
Capecitabine | Phase 2 | Pancreatic Cancer | - | - |
parsaclisib + itacitinib | Phase 2 | B-Cell Malignancies | - | - |
Oxaliplatin | Phase 2 | Solid Tumor | - | - |
MEDI4736 | Phase 2 | Solid Tumors | - | - |
Ruxolitinib 1.5% cream | Phase 2 | Vitiligo | - | - |
Regorafenib | Phase 2 | Pancreatic Cancer | - | - |
Osimertinib | Phase 2 | Lung Cancer | - | - |
MK-3475 | Phase 2 | Microsatellite-instability (MSI) High Colorectal Cancer (CRC) | - | - |
INCA000585 | Phase 2 | Immune Thrombocytopenia | - | - |
INCAGN01876 | Phase 2 | Advanced Malignancies | - | - |
INCAGN01949 | Phase 2 | Advanced Malignancies | - | - |
R-CHOP | Phase 2 | Non Hodgkins Lymphoma | - | - |
INCB001158 | Phase 2 | Biliary Tract Cancer (BTC) | - | - |
INCB177054 | Phase 2 | Solid Tumors | - | - |
ICS-LABA | Phase 2 | Moderate to Severe Asthma | - | - |
Pemigatinib | Phase 2 | Non-Small Cell Lung Cancer (NSCLC) | - | Patent 2040 |
Ruxolitinib 25 mg | Phase 2 | Multiple Myeloma | - | - |
Nivolumab | Phase 2 | B-cell Malignancies | - | - |
Asparaginase Erwinia Chrysanthemi | Phase 2 | Leukemia | - | - |
INCB013739 | Phase 2 | Type 2 Diabetes | - | - |
INCB000928 | Phase 2 | Anemia | - | - |
Ruxolitinib phosphate cream | Phase 2 | Psoriasis | - | Patent 2041 |
INCB054707 | Phase 2 | Hidradenitis Suppurativa | - | - |
Parsaclisib | Phase 2 | B-Cell Malignancies | - | - |
Ponatinib | Phase 2 | Philadelphia Positive | - | - |
Ruxolitinib 0.15% Cream QD | Phase 2 | Atopic Dermatitis | - | - |
INCB009471 | Phase 2 | HIV Infections | - | - |
INCB099280 | Phase 2 | Advanced Solid Tumor | - | - |
INCAGN02385 | Phase 2 | Endometrial Cancer | - | - |
Axatilimab | Phase 2 | Chronic Graft-versus-host-disease | - | - |
INCAGN02390 | Phase 2 | Melanoma | - | - |
Best available Treatment (BAT) | Phase 2 | Chronic Graft-versus-host-disease | - | - |
Gemcitabine | Phase 2 | Solid Tumors | - | - |
INCB018424 | Phase 2 | Rheumatoid Arthritis | - | - |
INCB028050 | Phase 2 | Rheumatoid Arthritis | - | - |
Prednisone or methylprednisolone | Phase 2 | Graft-versus-host Disease (GVHD) | - | - |
Ruxolitinib Phosphate | Phase 2 | Psoriasis | - | - |
Immune effector cell therapy | Phase 2 | Cytokine Release Syndrome | - | - |
Platinum-based chemotherapy | Phase 2 | Lung Cancer | - | - |
Chronic Graft-versus-host-disease
3 drugs in this indication
Melanoma
2 drugs in this indication
Solid Tumors
2 drugs in this indication
MPN (Myeloproliferative Neoplasms)
2 drugs in this indication
B-cell Malignancies
2 drugs in this indication
Graft-versus-host Disease (GVHD)
2 drugs in this indication
Hidradenitis Suppurativa
2 drugs in this indication
Polycythemia Vera
2 drugs in this indication
Nonsegmental Vitiligo With Genital Involvement
1 drug in this indication
Atopic Dermatitis
1 drug in this indication
Metastatic Squamous Non-Small Cell Lung Cancer
1 drug in this indication
Leukemia
1 drug in this indication
HIV Infections
1 drug in this indication
Biliary Tract Cancer (BTC)
1 drug in this indication
Type 2 Diabetes
1 drug in this indication
Philadelphia Positive
1 drug in this indication
Non-Small Cell Lung Cancer (NSCLC)
1 drug in this indication
Prurigo Nodularis
1 drug in this indication
Psoriasis
1 drug in this indication
Follicular Lymphoma
1 drug in this indication
Metastatic Merkel Cell Carcinoma
1 drug in this indication
Moderate to Severe Asthma
1 drug in this indication
Non-segmental Vitiligo
1 drug in this indication
Multiple Myeloma
1 drug in this indication
NonSegmental Vitiligo
1 drug in this indication
Diffuse Large B Cell Lymphoma
1 drug in this indication
Anemia
1 drug in this indication
Ovarian Cancer
1 drug in this indication
Advanced Solid Tumor
1 drug in this indication
Lymphoma
1 drug in this indication
Squamous Cell Carcinoma of the Anal Canal
1 drug in this indication
Endometrial Cancer
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Incyte Corporation's drug pipeline?→
CatalystAlert tracks 67 drug candidates in Incyte Corporation's (INCY) pipeline across Phase 3, Phase 2. Its lead program is Ruxolitinib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Incyte Corporation's next FDA catalyst?→
Incyte Corporation's (INCY) next tracked catalyst is a Phase 3 expected June 30, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track INCY biotech catalysts?→
Add INCY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Incyte Corporation's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.